National Guidelines for Cervical Cancer Prevention and Control

Objectives

Establish a national standard for cervical cancer prevention and control in Jamaica’s public health system, with the overarching aim of reducing incidence and mortality through early detection of precancerous changes, appropriate treatment or referral, and prevention of progression to invasive disease.[1][2][3]Cervical cancer is presented as largely preventable and usually curable when detected and treated early.[3]

• Strengthen organised Pap smear screening, particularly for women aged 25 to 54 years and women who have never been screened.[1][4]Promote screening at least once every three years, while annual testing is recommended unless otherwise indicated.[4][5]
• Detect cervical abnormalities before clinical presentation and identify precursor lesions for timely treatment, referral and follow-up.[2][5]
• Improve management of abnormal Pap smear results through standard cytological classification, repeat testing, colposcopy, histological assessment and treatment pathways.[1][6][5][7]
• Provide screening and follow-up guidance for women in special circumstances, including pregnancy, older age, hysterectomy, HIV infection, immunosuppression and prior cancer treatment.[8]
• Support early diagnosis, treatment and rehabilitation for people with suspected or confirmed cervical cancer, aiming to cure cancer, prolong useful life and improve quality of life.[6]
• Inform women about cervical cancer, screening purpose, possible discomfort, and the meaning of negative and positive results, recognising that a positive result does not itself establish a cancer diagnosis.[5]

The framework recognises persistent infection with high-risk human papillomavirus as the principal underlying cause of cervical cancer.[3]Smoking, immune suppression, hormonal contraceptive use, high parity and increased lifetime number of sexual partners may influence progression.[3][4]The document links well-organised screening programmes with reductions in cervical cancer incidence and mortality of at least 60%, and potentially up to 80%.[3]

Implementation

Implement the protocol as a standard operating approach throughout the public health system, combining accessible screening, quality-assured sample collection and laboratory processing, defined referral pathways, specialist care, client education, and active follow-up.[1][2][9][10]The guideline is to be distributed to Type I to V health centres and all hospitals under approval of the Director of Health Promotion and Protection.[4][5]

• Deliver screening through health clinics and centres, hospitals, private physicians’ offices, the Jamaica Cancer Society, satellite clinics, outreach programmes, workplace services, health fairs and mobile units.[9]Begin screening within three years of sexual activity commencing, while the guideline identifies no evidence supporting screening below age 18.[4]
• Apply age- and risk-based intervals, including three-yearly screening after two consecutive normal Pap tests for women aged 25 to 54 years up to age 65, more frequent testing where risk factors warrant it, and annual lifelong screening for HIV-positive or otherwise immunosuppressed women.[4][8]Discontinue screening at age 65 only where the required history of satisfactory negative smears is documented.[4]
• Prepare clients and collect specimens consistently by providing pre-test information, using appropriate equipment, collecting smears before digital vaginal examination, labelling slides and request forms consistently, fixing specimens correctly and dispatching them promptly to laboratories.[8][11]Advise clients to avoid vaginal suppositories, creams and foams for one week before examination and to avoid intercourse or douching on the preceding day.[11]
• Maintain trained personnel, appropriate clinical support for non-physician providers, confidential examination conditions, sterilisation capacity for reusable equipment where applicable, and safe storage of preservative alcohol.[10]Ensure facilities can receive results, recall clients, issue reminders, make referrals and arrange timely smear analysis, with a suggested maximum turnaround of three months from sample creation.[10]
• Refer women with abnormal cytology for further assessment and treatment, including gynaecological evaluation within six weeks for high-grade squamous intraepithelial lesions, atypical squamous cells where high-grade lesions cannot be excluded, and glandular abnormalities.[6]Use colposcopy for high-grade lesions, persistent abnormalities, unexplained cervical lesions or bleeding, and atypical glandular cells.[12]
• Use repeat smears, cryotherapy, loop electrosurgical excision procedure, cone biopsy, oncology or gynaecological referral, and specialist hospital care according to cytology, colposcopy and disease severity.[12][9][7]Manage pre-invasive disease in pregnancy without terminating the pregnancy, deferring specified non-invasive treatment until after delivery.[8][6]
• Provide education and counselling before referral to reduce anxiety, clarify issues and support informed choice by clients and family members.[9]Maintain referral links among primary care, family physicians, specialist services and, where necessary, palliative care.[9]
• Document services, interventions and outcomes in the cervical cancer register, submit timely reports, and actively follow up clients to support attendance at referred appointments.[9]

Development and implementation involve the Ministry of Health, hospitals, laboratories, the Jamaica Cancer Society, the National Family Planning Board, the University Hospital of the West Indies, and contributing specialists.[1]Treatment choices are to take account of available human, physical and financial resources.[6]The source does not specify a programme budget, funding mechanism, quantified resource plan, formal performance targets, audit system or comprehensive evaluation framework beyond registers, reporting, result tracking and clinical follow-up arrangements.[6][9][10]

Monitoring & Evaluation

Monitoring and accountability centre on screening uptake, timely laboratory processing, documented follow-up, referral completion, and clinical outcomes. The protocol provides several service-level measures and follow-up intervals, but does not establish a comprehensive national monitoring and evaluation framework with assigned responsibilities, targets, audit procedures, or a reporting schedule.[9][10][3][4]

• Monitor screening coverage, particularly among women aged 25 to 54 years and women who have never received a Pap smear. The Jamaica Lifestyle Survey 2008 found that 34.3% of women aged 15 to 74 years had never had a Pap smear.[4]
• Assess programme outcomes through cervical cancer incidence and mortality. The guideline cites an age-standardised incidence rate of 25.2 per 100,000 women for Kingston and St Andrew during 1993 to 1997.[3]
• Track screening intervals as a key determinant of expected disease reduction. Reported reductions in cumulative cervical cancer rates are 93% with one- or two-year screening, 91% with three-year screening, 84% with five-year screening, and 64% with ten-year screening.[4]
• Record services, interventions, and outcomes in the cervical cancer register, and monitor clients after treatment through their health facility.[9]
• Submit timely reports and actively follow up clients to support attendance at referred appointments.[9]
• Maintain systems to receive smear results, recall clients, issue reminders, and make referrals, with smear-result processing suggested within a maximum of three months from specimen collection.[10]
• Give clients a return date six weeks after Pap-smear collection to facilitate result communication and follow-up.[11]
• Repeat an unsatisfactory Pap smear after six weeks and refer a client for colposcopy after two consecutive unsatisfactory smears.[6]
• Repeat low-grade squamous intraepithelial lesion smears every six months for two consecutive years, refer clients for gynaecological evaluation if a follow-up result is atypical squamous cells of undetermined significance or worse, and return clients to routine screening when follow-up smears are negative for intraepithelial lesion or malignancy.[6]
• Provide gynaecological evaluation within six weeks for high-grade squamous intraepithelial lesions, atypical squamous cells where high-grade lesions cannot be excluded, and glandular abnormalities.[6]
• Use repeat Pap smears at six-month intervals for one or two years in specified post-colposcopy circumstances, returning clients to routine screening when results are negative and satisfactory.[9]
• Monitor specialised pathways for higher-risk groups, including annual and lifelong screening for immunosuppressed women and referral of HIV-positive women with cytology results of atypical squamous cells of undetermined significance or above for gynaecological evaluation.[8]
• Use clinical classification, referral, colposcopy, histology, treatment, and follow-up processes to manage abnormal results, while recognising that positive cytology does not itself confirm cancer.[2][5][7]

Formal surveillance arrangements are only partly evidenced through the Kingston and St Andrew Cancer Registry, the Jamaica Lifestyle Survey, the cervical cancer register, and service reporting requirements. The available material does not specify national indicator definitions, data-quality procedures, reporting frequency, evaluation methodology, performance targets, or a formal accountability framework.[3][4][9][10]

Costing & Financing

No programme budget, unit cost, financing plan, funding source, allocation, funding gap, resource-mobilisation mechanism, or quantified economic assumption is specified.[1][2][3][4][8][11][9][10][5][7]

• Recognise that treatment decisions are to be adapted to available human, physical, and financial resources, while seeking to support rehabilitation.[6]
• Require operational inputs for screening and follow-up, including trained personnel, appropriate clinical expertise for non-physician providers, facilities for gynaecological examination, specimen preservation and safe storage, equipment sterilisation where relevant, laboratory processing, result-receipt systems, client recall, reminders, and referral arrangements.[10]
• Use delivery channels that include health clinics and centres, hospitals, private physicians' offices, the Jamaica Cancer Society, satellite clinics, outreach programmes, workplace services, health fairs, and mobile units; however, the source does not cost these channels or identify their funding.[9]
• Provide diagnostic and treatment capacity through colposcopy, cryosurgery, loop excision, cone biopsy, specialist hospital care, oncology or gynaecological referral, and palliative care where necessary, without specifying associated resource requirements or financing.[12][9][7]

The material therefore identifies resource-dependent service components but provides no basis for estimating total costs, affordability, cost-effectiveness, funding requirements, or financing gaps.[6][9][10]